Back to News
Market Impact: 0.38
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The FDA approved Curium's BEXLUTRY, the first radioligand equivalent treatment for adult gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approval marks Curium's first FDA-approved radioligand therapy and expands treatment options in the oncology radiopharmaceutical market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.82
More News
- Tencent, Visa deepen payments push in China after regulatory green light
- Google's Gemini 4 Carbon looks like a diamond in the rough
- Healey Defends UK Budget, Warns 'Tough Decisions' Ahead
- Kalshi, co-founders hit with criminal charges in US state of Utah
- Trump methane policy rollback may have minimal impact on crude prices, EPA says
- Nvidia's $12.9 billion Hugging Face deal draws DOJ scrutiny